Vibostolimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MelanomaCarcinoma, Non-Small-Cell Lung

191 competitors in Melanoma

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 3

1122

Cotellic

Roche

Phase 3

213

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

394

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

355

Taxol

Teva

Phase 3

136

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

287

Libtayo

Regeneron

Phase 3

68

Opdualag

Bristol-Myers Squibb

Phase 3

49

Paraplatin

AAvyxa

Phase 3

1110

Tuoyi

SSun Yat-sen University

Phase 3

4Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Melanoma3 trials

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Active, not recruiting·Merck & Co.·Phase 1/2·NCT04305054·315 enrolled

A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A

Completed·Merck & Co.·Preclinical·NCT04305041·100 enrolled

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C

Completed·Merck & Co.·Preclinical·NCT04303169·146 enrolled

Advanced Solid Tumors1 trial

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Completed·Merck & Co.·Phase 1·NCT02964013·474 enrolled

Hematologic Malignancies1 trial

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Withdrawn·Merck & Co.·Phase 1/2·NCT06395090

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Preclinical·NCT04165070·450 enrolled

Details

Drug Info

Related News